While many Americans rely on generic drugs as an inexpensive way to treat common ailments, common essential medications can vary in quality from manufacturer to manufacturer and even batch to batch of, especially when a drug goes generic. The team at New Haven-based Valisure saw a market opportunity and developed techniques and technology to make sure that each batch of medicine they distribute has been tested for many of the most important properties, like dosage, dissolution and contaminants.
Our speaker at WHIPgroup’s Meetup on Tuesday, June 16, is David Light, CEO of Valisure. A repeat entrepreneur who’s worked for several successful biotech startups. David is a repeat entrepreneur who’s worked for several successful biotech startups. He will share his insights into the current world of healthcare and the opportunities presenting themselves to biotech leaders with the background and drive to get things done.
WHIPgroup has prevailed in another patent appeal before the Patent Trial and Appeal Board (PTAB). The invention relates to an adjustable piston with an inner plastic nut that helps withstand high frequency pulsing loads. The [Read More…]
Earlier this month WHIPgroup asked the Supreme Court to take up the important issue of whether a court can overlook factual allegations in a patentee’s infringement complaint at the pleading stage and find that the [Read More…]
WHIPgroup Successfully obtained patent allowance with an Appeal Brief. The invention is directed to an agitator ball mill, and has cams with specific ratios that improve mixing, cooling, and durability. The Patent Office rejected all [Read More…]